drugset / Trial / NCT02320630
Combination Therapy Prevents the Relapse of RA
Unknown
240 enrolled
Peking University First Hospital
Beijing Hospital · collabBeijing Jishuitan Hospital · collabBeijing Shijitan Hospital, Capital Medical University · collabPeking University People's Hospital · collabPeking University Shougang Hospital · collabPeking University Third Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial aims to compare the cost effective and effect of preventing recurrence by different treatment of TFP and HCQ combined SSZ for remittent RA.
Timeline
- Start
- 2015-10
- Primary completion
- 2017-02
- Completion
- 2020-09
Outcome
Met primary endpoint
paper 10/22 (45.5%) vs. 17/20 (85.0%), χ2 = 5.517, P = 0.019 PMID 36525606 ↗
Publications
- Zhao J, Zhou W, Wu Y, Yan X, Yang L, Zhang Z. Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study). Chin Med J (Engl). 2022 Sep 20;135(18):2200-2209. doi: 10.1097/CM9.0000000000002336.
- Zhao J, Zhou W, Wu Y, Ji P, Yang L, Yan X, Zhang Z. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study). BMC Med Inform Decis Mak. 2021 Mar 4;21(1):83. doi: 10.1186/s12911-021-01449-2.
- Fan Y, Yang X, Zhao J, Sun X, Xie W, Huang Y, Li G, Hao Y, Zhang Z. Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis. Arthritis Res Ther. 2019 May 21;21(1):123. doi: 10.1186/s13075-019-1906-y.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entanercept | Unknown | — | — |
| Subject | HCQ | Unknown | — | — |
| Subject | MTX | Unknown | — | — |
Indications
No indication recorded.